Camlin Fine Sciences Ltd Q2 FY2023 Concall Summary

Key Takeaways

• Record revenue, margin squeeze: Highest-ever consolidated revenue was offset by a ~INR 22 Cr energy-cost spike in Europe and a catechol-driven gross margin drag, with the next two quarters called out as challenging.
• Vanillin is the near-term catalyst: Trial runs are done and commercial production awaits one final approval; once online, vanillin turns the loss-making catechol stream profitable and lifts blended margins.
• China plant remains idle: The subsidiary is still shut under a Supreme Court order; management is exploring an alternative aromatic product use but offered no timeline.
• Tax rate optics are messy: The consolidated tax rate looks high because losses in some geographies cannot offset profits elsewhere, and a year-end India profit true-up inflated the quarterly provision.
• What to watch next quarter: Whether the final vanillin approval arrives and production begins, the trajectory of European gas prices and any subsidy relief, and how management rebalances the portfolio through the demand slowdown it flagged.

Vanillin: The Margin Pivot

• Status: Trial runs at the Dahej vanillin plant are complete; commercial production is waiting on one last approval to begin at full scale.
• Catechol economics transform: Without vanillin, rising diphenol output produces more catechol than hydroquinone, and catechol has been in a chronic global oversupply, dragging margins. Once vanillin consumes that catechol internally, a loss-making stream becomes profit-making.
• Cost parity claim: Management stated that with vanillin onstream, the company's cost structure will be very similar to competitors.
• Operating floor: The plant design requires a minimum 50% utilisation rate, a design constraint rather than an economic breakeven point.
• Pricing context: Vanillin prices currently sit at \$15–\$20; management declined to give an EBITDA contribution number, saying it will evolve with market conditions.

Momaya: "With the vanillin facility coming in, that catechol, which was a loss-making business, has returned into a profit-making business, which will mean that our cost structures will be very similar to our competitors."

Margin Headwinds & Energy Exposure

• Energy cost hit: The Russia-Ukraine crisis drove a ~INR 22 Cr sequential increase in energy costs at the Italian diphenols subsidiary, directly compressing overall margins.
• Catechol mix effect: Sequential gross margin softening was primarily because higher diphenol production yields proportionally more catechol, and catechol prices remain under pressure.
• European gas uncertainty: Management called gas prices extremely difficult to predict and said any Italian government energy subsidy, while possible, cannot be relied upon.
• Long-term margin ambition: At full scale with all businesses balanced, management eyes high-teens EBITDA margins, with potential to reach 20%, though this depends on FX, raw materials, and the war situation.

Momaya: "It's very difficult to say with this volatility right now. Extremely difficult to say what will happen to gas prices."

Demand & Near-Term Outlook

• Next two quarters flagged as challenging: Management cited demand slowdown, price corrections, and falling raw material prices, and said it is actively rebalancing the product portfolio to focus on less-exposed products.
• Hydroquinone pricing: HQ prices rose over 50% since Dahej production began, peaking near \$11.50–\$12, but have since corrected to around \$10. India-produced HQ is now almost entirely consumed captively for downstream derivatives.
• Catechol oversupply structural, not China-driven: Global catechol capacity has exceeded demand for years; the oversupply is not primarily because of the China vanillin plant being absent.
• H2 FY23 revenue view: Management expects the second half to be broadly similar to the first half, with vanillin adding upside and some price corrections weighing on the top line.

Momaya: "The next two quarters are challenging because there's demand slow down, there is price corrections. And of course, we also see some raw material prices coming off. So we are trying to see and balance based on what the market conditions are, we are trying to balance on the product portfolio, rearrange, realign some of the products and focus on those more than other ones where demand could be a challenge."

Subsidiary & Geographic Updates

• MEHQ re-entry: The company restarted MEHQ sales this quarter after a one-year hiatus.
• Lockheed Martin: Producing material for Lockheed's first commercial battery, with supply targeted for mid-next year; additional business under discussion.

Tax & Balance Sheet

• Consolidated tax rate distortion: The high apparent tax rate arises because losses in some subsidiaries cannot be offset against profits in others; profit-making entities are in the 30%–35% range, but including loss-makers inflates the consolidated rate.
• India tax true-up: A higher year-end annual profit estimate versus the earlier lower estimate created a larger arithmetic tax charge this quarter; India remains under the MAT regime on a cash basis for the next two years.
• Deferred tax assets: Capitalisation of the diphenol plant last year and the vanillin plant this year is hitting deferred tax assets.
• Debt pathway: Cash accruals will be directed to debt reduction; if the IFC converts its FCCB, debt drops by INR 100 Cr without cash outflow. Long-term debt barring the IFC and Exim ECB will stay for five to six years; revolving credit will remain.
• No further capex planned: Management has no further capex plans at this point.

Guidance & Commitments

Key Metrics